BNT162b2 mRNA COVID-19 Vaccination (BNTCV) in Patients (Pts) Having Hematological Malignancies (HM): Early tolerance with telemedicine application connecting and antibody anti-Spike IgG response (AcAS)

Pts with HM and particularly those under therapy or with secondary immune deficiency have been reported to have a low or delayed specific immune response. In addition, pts receiving rituximab for either HM or auto-immune disease presented a low specific antibody response. Daratumumab, an anti-CD38 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Jean-Francois, Bonnet, Emmanuel, Velensek, Marion, Wisniewski, Emma, Heraud, Sophie, Boustany, Rania, David, Celeste, Dinet, Jerome, Sicard, Roland, Daures, Jean Pierre, Bonifacy, Marion, Mousset, Lysiane, Goffard, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
803.Emerging Diagnostic Tools and Techniques
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701686/
http://dx.doi.org/10.1182/blood-2021-154539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701686/
http://dx.doi.org/10.1182/blood-2021-154539

Ejemplares similares